Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
JAMA Pediatrics · 01.02.2025 · 179 (2) · 179
DOI: 10.1001/jamapediatrics.2024.5572 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.02.2025. Verfasst von Heidi L Moline und 30 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preven…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCIRD CDC HHS, NIAID NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Importance During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer’s maternal RSV vaccine. Postlicensure studies are needed to assess prevention product impact and effectiveness.
Objective
To compare the epidemiology and disease burden of medically attended RSV-associated acute respiratory illness (ARI) among children younger than 5 years during the 2023-2024 RSV season with 3 prepandemic RSV seasons (2017-2020), estimate nirsevimab effectiveness against medically attended RSV-associated ARI, and compare nirsevimab binding site mutations among circulating RSV in infants with and without nirsevimab receipt. Design, Setting, and Participants This study included prospective population-based surveillance for medically attended ARI with systematic molecular testing for RSV and whole-genome sequencing of RSV positive samples, as well as a test-negative case-control design to estimate nirsevimab effectiveness. The study was conducted in 7 academic pediatric medical centers in the United States with data from RSV seasons (September 1 through April 30) in 2017 through 2020. Participants were children younger than 5 years with medically attended ARI. Exposure For the nirsevimab effectiveness analyses, nirsevimab receipt among infants younger than 8 months as of or born after October 1, 2023. Main Outcome and Measure Medically attended RSV-associated ARI.
Results
Overall, 28 689 children younger than 5 years with medically attended ARI were enrolled, including 9536 during September 1, 2023, through April 30, 2024, and 19 153 during the same calendar period of 2017-2020. Of these children, 16 196 (57%) were male, and 12 444 (43.4) were female; the median (IQR) age was 15 (6-29) months. During 2023-2024, the proportion of children with RSV was 23% (2199/9490) among all medically attended episodes, similar to 2017-2020. RSV-associated hospitalization rates in 2023-2024 were similar to average 2017-2020 seasonal rates with 5.0 (95% CI, 4.6-5.3) per 1000 among children younger than 5 years; the highest rates were among children aged 0 to 2 months (26.6; 95% CI, 23.0-30.2). Low maternal RSV vaccine uptake precluded assessment of effectiveness. Overall, 10 of 765 case patients (1%) who were RSV positive and 126 of 851 control patients (15%) who were RSV negative received nirsevimab. Nirsevimab effectiveness was 89% (95% CI, 79%-94%) against medically attended RSV-associated ARI and 93% (95% CI, 82%-97%) against RSV-associated hospitalization. Among 229 sequenced specimens, there were no differences in nirsevimab binding site mutations by infant nirsevimab receipt status. Conclusions and Relevance This analysis documented the continued high burden of medically attended RSV-associated ARI among young children in the US. There is a potential for substantial public health impact with increased and equitable prevention product coverage in future seasons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
- US Public Health Service, Rockville, Maryland.
- Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Vanderbilt University Medical Center, Nashville, Tennessee.
Förderung
- NCIRD CDC HHS
- NIAID NIH HHS
Zitieren
APA
Moline, H. L., Toepfer, A. P., Tannis, A., Weinberg, G. A., Staat, M. A., Halasa, N. B., Boom, J. A., Klein, E. J., Williams, J. V., Schuster, J. E., Goldstein, L., McKeever, E. R., Kalman, C., Paden, C., Atherton, L., Aggarwal, M., Roychoudhury, P., Piedra, P. A., Sahni, L. C., …, & New Vaccine Surveillance Network Collaborators (2025). Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatrics, 179(2), 179. https://doi.org/10.1001/jamapediatrics.2024.5572
Vancouver
Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, et al. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatrics. 2025;179(2):179. doi:10.1001/jamapediatrics.2024.5572
BibTeX
@article{Moline2025,
author = {Moline, Heidi L and Toepfer, Ariana P and Tannis, Ayzsa and Weinberg, Geoffrey A and Staat, Mary A and Halasa, Natasha B and Boom, Julie A and Klein, Eileen J and Williams, John V and Schuster, Jennifer E and Goldstein, Leah and McKeever, Erin R and Kalman, Casey and Paden, Clinton and Atherton, Lydia and Aggarwal, Megha and Roychoudhury, Pavitra and Piedra, Pedro A and Sahni, Leila C and Stewart, Laura S and Selvarangan, Rangaraj and Michaels, Marian G and Schlaudecker, Elizabeth P and Szilagyi, Peter G and Englund, Janet A and Clopper, Benjamin R and Thornburg, Natalie J and Derado, Gordana and McMorrow, Meredith L and Dawood, Fatimah S and New Vaccine Surveillance Network Collaborators, New Vaccine Surveillance Network Collaborators},
title = {Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024},
journal = {JAMA Pediatrics},
year = {2025},
volume = {179},
number = {2},
pages = {179},
doi = {10.1001/jamapediatrics.2024.5572}
}
EUVIMED